{"nctId":"NCT03917459","briefTitle":"COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure","startDateStruct":{"date":"2019-04-16","type":"ACTUAL"},"conditions":["Heart Failure","Heart Failure, Systolic","Erectile Dysfunction"],"count":27,"armGroups":[{"label":"LCZ696","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696","Drug: LCZ696 matching placebo"]},{"label":"Enalapril","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril matching placebo","Drug: Enalapril"]}],"interventions":[{"name":"LCZ696","otherNames":[]},{"name":"Enalapril matching placebo","otherNames":[]},{"name":"Enalapril","otherNames":[]},{"name":"LCZ696 matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Patients with a diagnosis of chronic heart failure (NYHA class II) and reduced ejection fraction (LVEF \\< 40%)\n* Patients must be living in a stable and sexually active heterosexual partnership for at least 6 months prior study start\n* Patients must have a mild to moderate erectile dysfunction (determined by using the IIEF-5 questionnaire)\n* Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks prior study start\n* Patients must be literate in German\n\nKey Exclusion Criteria:\n\n* History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes, ACEIs, ARBs or NEP inhibitors, as well as known or suspected contraindications to the study drugs\n* Previous history of intolerance to recommended target doses of ACEIs or ARBs\n* Known history of angioedema\n* Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)\n* Symptomatic hypotension\n* Impaired renal function\n* Penile anatomical defects and Peyronie's disease\n* Diabetes mellitus Type I or insulin-dependent Type II\n* Known prostate cancer","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Erectile Function Score Using Index of Erectile Function (IIEF-15)","description":"The International Index of Erectile Function (IIEF-15) was used to assess erectile function in male patients with chronic heart failure. The IIEF-15 is a patient self-reported assessment of erectile dysfunction (ED) and consists of 15 questions assessing different aspects associated with ED. The domain evaluating erectile function consists of items 1, 2, 3, 4, 5 \\& 15 and its total score was used here. Total score range =1-30. Items 1-5 is 6-point Likert-type scale from '0' (= No sexual activity), '1' (=Almost never or never) to '5' (= Almost always or always). Items 15 is 5-point Likert-type scale from '1' (= very low) to '5 '(= very high). Higher score indicates better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"2.15"},{"groupId":"OG001","value":"12.2","spread":"2.00"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline in Self-reported Frequency of Sexual Activity Per Week","description":"Assessment of early-onset effect and end of study effect, regarding improvement in sexual activity, using patient's self-reported frequency of sexual activity per week. Patient was asked to complete a diary assessing sexual activity on a weekly basis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.59"},{"groupId":"OG001","value":"-1.1","spread":"1.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"3.13"},{"groupId":"OG001","value":"-2.0","spread":"3.07"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline in NT-proBNP Levels","description":"Change in n-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels compared to baseline assessed at Week 4 and Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-369.00","spread":null},{"groupId":"OG001","value":"-43.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-208.50","spread":null},{"groupId":"OG001","value":"-189.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Hypotension","Dental caries","Toothache","Oedema peripheral","Bronchitis"]}}}